Compare Global X FTSE Southeast Asia ETF (ASEA) vs Medtronic PLC (MDT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Medtronic PLC — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.65, while Medtronic PLC trades at $84.19 (market cap $107.36B). The key difference: Medtronic PLC pays a 3.43% dividend while Global X FTSE Southeast Asia ETF pays none, and Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| ASEA | MDT | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $20.65 | $105.35 |
52-Week Low | $16.31 | $73.75 |
Market Cap | — | $107.36B |
Enterprise Value | — | $126.10B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.
The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.
Medtronic (MDT) trades at $83.87, up 1.8% with a bullish technical signal and strong fundamental performance. The stock shows consistent earnings beats with Q1 2026 EPS of $1.55 exceeding expectations, while revenue growth accelerated to $33.54B in 2025. Analyst consensus remains strongly positive with 58% buy ratings and a $97.31 price target, representing 16% upside potential from current levels.
MDT presents an attractive investment case with solid profitability metrics, dividend aristocrat status, and accelerating revenue growth. Key risks include increasing debt levels (debt-to-asset ratio rose to 31.11% in 2025) and margin pressure from tariffs. The company's strategic acquisitions and innovation in cardiovascular and neuroscience segments support long-term growth prospects despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
